Sign In
Buy HAE
$65.88
-0.490 (-0.738%)
At Close: Jun 03, 2026
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
09:02am, Tuesday, 10'th May 2022
Haemonetics (HAE) delivered earnings and revenue surprises of 8.33% and 2.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Medical Product Stocks Set to Beat on Earnings This Season
09:03am, Monday, 09'th May 2022
Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how CGC, HAE and ALC are poised ahead of their earnings releases.
Clover Health (CLOV) to Report Q1 Earnings: What's in Store?
04:18pm, Friday, 06'th May 2022 Zacks Investment Research
Clover Health's (CLOV) first-quarter results are likely to reflect benefits from Clover Assistant management.
Viemed Healthcare, Inc. (VMD) Lags Q1 Earnings Estimates
10:15pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Viemed Healthcare, Inc. (VMD) delivered earnings and revenue surprises of -33.33% and 1.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
07:00pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?
10:37am, Tuesday, 03'rd May 2022 Zacks Investment Research
Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in the Pharmaceutical segment.
AMN Healthcare (AMN) to Report Q1 Earnings: What's in Store?
10:35am, Tuesday, 03'rd May 2022 Zacks Investment Research
AMN Healthcare's (AMN) first-quarter results are likely to reflect solid demand in some of the areas of its business.
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
12:25pm, Monday, 02'nd May 2022 Zacks Investment Research
DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect strong performance at Technologies & Equipment business.
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
12:21pm, Monday, 02'nd May 2022 Zacks Investment Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards?
12:40pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
PerkinElmer's (PKI) first-quarter results are likely to reflect strong performance at the Diagnostics segment.
AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?
12:39pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
AmerisourceBergen's (ABC) fiscal second-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
What's in Store for West Pharmaceutical's (WST) Q1 Earnings?
01:47pm, Monday, 25'th Apr 2022 Zacks Investment Research
West Pharmaceutical's (WST) first-quarter results are likely to reflect strength in the Proprietary Products business.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
01:46pm, Monday, 25'th Apr 2022 Zacks Investment Research
DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.
Baxter (BAX) to Report Q1 Earnings: What's in the Offing?
01:16pm, Thursday, 21'st Apr 2022 Zacks Investment Research
Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.
Here's Why You Should Hold on to Haemonetics (HAE) For Now
02:29pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Investors are optimistic about Haemonetics (HAE) given the strength in its Hemostasis Management franchise and increased product uptake.
